ReviewTranslational pediatrics2026
Pediatric health: mechanistic insights into inflammatory diseases and emerging therapeutic pathway-targeted approaches.
Review in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric inflammatory diseases, including juvenile idiopathic arthritis, pediatric inflammatory bowel disease, asthma, Kawasaki disease, and multisystem inflammatory syndrome in children, are an increasing global health concern. These conditions arise from dysregulated immune responses shaped by genetic susceptibility, environmental exposures, and the distinctive features of the developing pediatric immune system. This review presents a mechanism-centered overview of pediatric inflammation, emphasizing immune ontogeny, innate and adaptive immune dysregulation, cytokine signaling, inflammasome activation, oxidative stress, and the gut-immune axis. It also highlights emerging pathway-targeted therapies, including cytokine blockade, JAK inhibitors, microbiome-based interventions, and gene-editing strategies, with attention to their relevance for pediatric precision medicine. Early, mechanism-based intervention during critical developmental windows may improve long-term outcomes and reduce the lifetime burden of inflammatory disease. Overall, this review provides a concise, pediatric-focused perspective on how developmental immunology and targeted therapeutics can inform more precise and effective management of childhood inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.